WINTON GROUP Ltd Purchases 33,613 Shares of The Cooper Companies, Inc. $COO

Posted by on Sep 12th, 2026

WINTON GROUP Ltd grew its holdings in shares of The Cooper Companies, Inc. (NASDAQ:COO – Free Report) by 379.0% during the second quarter, HoldingsChannel reports. The institutional investor owned 42,483 shares of the medical device company’s stock after buying an additional 33,613 shares during the period. WINTON GROUP Ltd’s holdings in Cooper Companies were worth $3,046,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of COO. Engineers Gate Manager LP lifted its position in shares of Cooper Companies by 8,637.7% during the second quarter. Engineers Gate Manager LP now owns 249,897 shares of the medical device company’s stock worth $17,920,000 after purchasing an additional 247,037 shares during the last quarter. NewEdge Advisors LLC grew its holdings in shares of Cooper Companies by 286.2% in the second quarter. NewEdge Advisors LLC now owns 12,780 shares of the medical device company’s stock worth $916,000 after purchasing an additional 9,471 shares during the last quarter. IFP Advisors Inc grew its holdings in shares of Cooper Companies by 248.8% in the second quarter. IFP Advisors Inc now owns 6,108 shares of the medical device company’s stock worth $438,000 after purchasing an additional 4,357 shares during the last quarter. Squarepoint Ops LLC increased its stake in Cooper Companies by 900.0% in the 2nd quarter. Squarepoint Ops LLC now owns 52,101 shares of the medical device company’s stock worth $3,736,000 after buying an additional 46,891 shares during the period. Finally, Baird Financial Group Inc. lifted its holdings in Cooper Companies by 177.9% during the 2nd quarter. Baird Financial Group Inc. now owns 19,748 shares of the medical device company’s stock valued at $1,416,000 after buying an additional 12,643 shares in the last quarter. 24.39% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Cooper Companies

Here are the key news stories impacting Cooper Companies this week:

  • Positive Sentiment: Cooper reported adjusted fiscal Q3 earnings of $1.15 per share, ahead of the approximately $1.11–$1.12 consensus, with earnings up from $0.49 a year earlier. Cost controls and continued fertility-related growth helped offset weakness elsewhere. Cooper Companies Bets on Fertility Growth Despite Weakness in CooperVision
  • Positive Sentiment: The board authorized an additional $1 billion of repurchases, bringing the total buyback authorization to $3 billion. The program could support per-share earnings and signal management believes COO shares are undervalued. Cooper Outlines Q4 EPS and Adds to Buyback Authorization
  • Neutral Sentiment: Cooper completed a strategic review but chose not to pursue a sale or separate transaction for CooperSurgical. Keeping the business preserves its fertility-growth opportunity, but investors had apparently anticipated a potential deal or value-unlocking action. Cooper Cos. Stock Drops After Soft Outlook and No Deal
  • Negative Sentiment: Revenue rose only about 1% to $1.066 billion, missing the roughly $1.10 billion consensus. U.S. channel destocking and inventory reductions pressured CooperVision, raising concerns about near-term demand and sales momentum. COO Q3 Earnings Top Estimates, Revenues Miss on Destocking
  • Negative Sentiment: Management reduced fiscal 2026 earnings guidance to $4.51–$4.55 per share and issued fourth-quarter guidance of $1.05–$1.09, below prior expectations. The weaker outlook triggered multiple analyst downgrades and price-target cuts, including from Baird, UBS, JPMorgan and William Blair.
  • Negative Sentiment: Law firms have announced securities-fraud investigations connected with the post-earnings decline. These notices are often promotional, but they add to negative investor sentiment and potential legal uncertainty. Securities Fraud Investigation Into Cooper Companies Announced

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. Weiss Ratings reissued a “sell (d)” rating on shares of Cooper Companies in a research report on Friday, September 4th. Needham & Company LLC lowered their price target on Cooper Companies from $86.00 to $73.00 and set a “buy” rating for the company in a report on Thursday. UBS Group dropped their price objective on Cooper Companies from $75.00 to $66.00 and set a “neutral” rating on the stock in a research note on Thursday. The Goldman Sachs Group set a $61.00 price objective on Cooper Companies in a report on Wednesday, May 27th. Finally, BNP Paribas Exane decreased their target price on Cooper Companies from $95.00 to $92.00 and set an “outperform” rating for the company in a research report on Monday, June 8th. Five analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Cooper Companies has a consensus rating of “Hold” and a consensus target price of $71.47.

Check Out Our Latest Research Report on COO

Cooper Companies Price Performance

NASDAQ COO opened at $53.91 on Friday. The company has a market cap of $10.51 billion, a PE ratio of 18.40, a P/E/G ratio of 1.45 and a beta of 0.82. The firm’s 50 day moving average price is $71.62 and its 200-day moving average price is $69.70. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.78 and a current ratio of 1.22. The Cooper Companies, Inc. has a 52-week low of $51.01 and a 52-week high of $89.83.

Cooper Companies (NASDAQ:COO – Get Free Report) last announced its earnings results on Wednesday, September 9th. The medical device company reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.12 by $0.03. Cooper Companies had a return on equity of 10.90% and a net margin of 13.46%.The business had revenue of $1.07 billion for the quarter, compared to analysts’ expectations of $1.10 billion. During the same quarter last year, the firm earned $0.49 EPS. The business’s revenue for the quarter was up .5% on a year-over-year basis. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. Sell-side analysts forecast that The Cooper Companies, Inc. will post 4.53 EPS for the current fiscal year.

Cooper Companies declared that its Board of Directors has initiated a share repurchase program on Wednesday, September 9th that allows the company to buyback $3.00 billion in outstanding shares. This buyback authorization allows the medical device company to repurchase up to 22.7% of its shares through open market purchases. Shares buyback programs are typically an indication that the company’s management believes its stock is undervalued.

Cooper Companies Profile

(Free Report)

Cooper Companies, Inc is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company develops, manufactures and markets products through two primary business segments: CooperVision and CooperSurgical.

CooperVision specializes in contact lenses, including daily disposable, toric, multifocal, multifocal toric, specialty and myopia-management lenses. Its products are designed to address a range of vision-correction needs, including astigmatism, presbyopia and irregular corneas.

Featured Stories

Want to see what other hedge funds are holding COO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for The Cooper Companies, Inc. (NASDAQ:COO – Free Report).

Institutional Ownership by Quarter for Cooper Companies (NASDAQ:COO)

Receive News & Ratings for Cooper Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies and related companies with MarketBeat.com's FREE daily email newsletter.